Multiple Sclerosis

Latest News

April 29th 2020

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

April 23rd 2020

Siponimod Shows Long-Term Benefit for Secondary Progressive MS

By Matt Hoffman

April 15th 2020

What Role Does Age Play in Multiple Sclerosis?

By Matt Hoffman

February 27th 2020

Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration

By Marco Meglio

September 13th 2019

Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

By Matt Hoffman

Latest Videos

Clinical Trial Design and Personalized Medicine in Multiple Sclerosis

Shared Decision-Making in Multiple Sclerosis Treatment

The Potential of NLRX1 in Immune Regulation and Neuroprotection for Inflammatory Neurodegenerative Disorders: Marjan Gharagozloo, PhD

Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh

Benefits of Telemedicine and Access to Treatments for Multiple Sclerosis: Jai Perumal, MD

Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches

Addressing Inflammation Upon the Diagnosis of MS

Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD

Defining the Utility of PIRA in Practice

Multiple Sclerosis Disease Course and Classification

CME Content

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

Video

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

Audio

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

More News

Siponimod Cleared for Treatment of Secondary Progressive MS

ByMatt Hoffman

March 27th 2019

Marketed as Mayzent, the selective sphingosine 1-phosphate receptor modulator is the first treatment for patients with active secondary progressive multiple sclerosis in almost 15 years.

Siponimod NDA Accepted by FDA for Secondary Progressive MS

ByJenna Payesko

October 9th 2018

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.

Multiple Sclerosis

Latest News

Latest Videos

Clinical Trial Design and Personalized Medicine in Multiple Sclerosis

Shared Decision-Making in Multiple Sclerosis Treatment

The Potential of NLRX1 in Immune Regulation and Neuroprotection for Inflammatory Neurodegenerative Disorders: Marjan Gharagozloo, PhD

Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh

Benefits of Telemedicine and Access to Treatments for Multiple Sclerosis: Jai Perumal, MD

Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches

Addressing Inflammation Upon the Diagnosis of MS

Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD

Defining the Utility of PIRA in Practice

Multiple Sclerosis Disease Course and Classification

CME Content

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

More News

Siponimod Cleared for Treatment of Secondary Progressive MS

Siponimod NDA Accepted by FDA for Secondary Progressive MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies

Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL